TISIDB

Summary
Symbol	DPYS
Name	dihydropyrimidinase
Aliases	DHPase; dihydropyrimidine amidohydrolase; hydantoinase
Chromosomal Location	8q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	-
Domain	PF01979 Amidohydrolase family
Function	Catalyzes the second step of the reductive pyrimidine degradation, the reversible hydrolytic ring opening of dihydropyrimidines. Can catalyze the ring opening of 5,6-dihydrouracil to N-carbamyl-alanine and of 5,6-dihydrothymine to N-carbamyl-amino isobutyrate.

> Gene Ontology [ TOP ]
Biological Process	GO:0006206 pyrimidine nucleobase metabolic process GO:0006208 pyrimidine nucleobase catabolic process GO:0006210 thymine catabolic process GO:0006212 uracil catabolic process GO:0006213 pyrimidine nucleoside metabolic process GO:0009112 nucleobase metabolic process GO:0009116 nucleoside metabolic process GO:0009164 nucleoside catabolic process GO:0019439 aromatic compound catabolic process GO:0019482 beta-alanine metabolic process GO:0019859 thymine metabolic process GO:0019860 uracil metabolic process GO:0034655 nucleobase-containing compound catabolic process GO:0044270 cellular nitrogen compound catabolic process GO:0046113 nucleobase catabolic process GO:0046135 pyrimidine nucleoside catabolic process GO:0046700 heterocycle catabolic process GO:0051259 protein oligomerization GO:0051260 protein homooligomerization GO:0051262 protein tetramerization GO:0051289 protein homotetramerization GO:0072527 pyrimidine-containing compound metabolic process GO:0072529 pyrimidine-containing compound catabolic process GO:1901136 carbohydrate derivative catabolic process GO:1901361 organic cyclic compound catabolic process GO:1901565 organonitrogen compound catabolic process GO:1901657 glycosyl compound metabolic process GO:1901658 glycosyl compound catabolic process
Molecular Function	GO:0002054 nucleobase binding GO:0002058 uracil binding GO:0002059 thymine binding GO:0002061 pyrimidine nucleobase binding GO:0004157 dihydropyrimidinase activity GO:0016597 amino acid binding GO:0016810 hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds GO:0016812 hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds, in cyclic amides GO:0031406 carboxylic acid binding GO:0043168 anion binding GO:0051219 phosphoprotein binding
Cellular Component	-

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa00240 Pyrimidine metabolism hsa00410 beta-Alanine metabolism hsa00770 Pantothenate and CoA biosynthesis hsa00983 Drug metabolism - other enzymes hsa01100 Metabolic pathways
Reactome	R-HSA-1430728: Metabolism R-HSA-15869: Metabolism of nucleotides R-HSA-73621: Pyrimidine catabolism R-HSA-73848: Pyrimidine metabolism

Summary
Symbol	DPYS
Name	dihydropyrimidinase
Aliases	DHPase; dihydropyrimidine amidohydrolase; hydantoinase
Chromosomal Location	8q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between DPYS and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	DPYS
Name	dihydropyrimidinase
Aliases	DHPase; dihydropyrimidine amidohydrolase; hydantoinase
Chromosomal Location	8q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of DPYS in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	DPYS
Name	dihydropyrimidinase
Aliases	DHPase; dihydropyrimidine amidohydrolase; hydantoinase
Chromosomal Location	8q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of DPYS in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.255	0.675
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-1.399	0.146
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	1.47	0.0692
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.19	0.753
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.387	0.727
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.916	0.467
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	1.141	0.181
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.046	0.972
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	2.275	0.0781
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.273	0.88
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	-0.817	0.764
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.688	0.0362

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of DPYS in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	7.4	6.8	0.6	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	7.4	8.5	-1.1	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	4.8	5.9	-1.1	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	7.7	9.1	-1.4	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	11.1	0	11.1	0.36
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	20	0	20	0.357
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	5.3	0	5.3	0.507
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	0	4.5	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	6.2	0	6.2	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	DPYS
Name	dihydropyrimidinase
Aliases	DHPase; dihydropyrimidine amidohydrolase; hydantoinase
Chromosomal Location	8q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of DPYS. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	DPYS
Name	dihydropyrimidinase
Aliases	DHPase; dihydropyrimidine amidohydrolase; hydantoinase
Chromosomal Location	8q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of DPYS. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by DPYS. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	DPYS
Name	dihydropyrimidinase
Aliases	DHPase; dihydropyrimidine amidohydrolase; hydantoinase
Chromosomal Location	8q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of DPYS. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	DPYS
Name	dihydropyrimidinase
Aliases	DHPase; dihydropyrimidine amidohydrolase; hydantoinase
Chromosomal Location	8q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of DPYS expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	DPYS
Name	dihydropyrimidinase
Aliases	DHPase; dihydropyrimidine amidohydrolase; hydantoinase
Chromosomal Location	8q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between DPYS and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	DPYS
Name	dihydropyrimidinase
Aliases	DHPase; dihydropyrimidine amidohydrolase; hydantoinase
Chromosomal Location	8q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting DPYS collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse DPYS